Plain language summary on “Interim analyses of the multinational real‐world prospective cohort HEM‐POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A”

Documenti analoghi

• A post hoc analysis of PROTECT VIII kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A
  di: Sanjay Ahuja, et al.
  Pubblicazione: (2024)
• A post hoc analysis of PROTECT VIII Kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A
  Pubblicazione: (2024)
• Real‐World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing HEM ‐ POWR Study
  di: Mark T. Reding, et al.
  Pubblicazione: (2025)
• Recombinant factor IX Fc for the treatment of hemophilia B
  di: Rolf Ljung, et al.
  Pubblicazione: (2024)
• Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real‐world: The retrospective IMAGE study
  di: Olivier Decaux, et al.
  Pubblicazione: (2024)